Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14910]

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer

Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast...

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

Glitch in protein synthesis could affect tumour growth

Glitch in protein synthesis could affect tumour growth

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...

Next-gen vaccines offer new hope against glioblastoma

Next-gen vaccines offer new hope against glioblastoma

“Draw me a cell”: Generative AI takes on clinical predictions in cancer

“Draw me a cell”: Generative AI takes on clinical predictions in cancer

Double trouble for triple-negative breast cancer

Double trouble for triple-negative breast cancer

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...

How the scars of demolished brain tumours seed relapse

How the scars of demolished brain tumours seed relapse

More from ecancer